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Background: Racial and ethnic disparities persist in stroke occurrence, recurrence, morbidity and mortality.
Uncontrolled hypertension (HTN) is the most important modifiable risk factor for stroke risk. Home health care
organizations care for many patients with uncontrolled HTN and history of stroke; however, recurrent stroke
prevention has not been a home care priority. We are conducting a randomized controlled trial (RCT) to compare
the effectiveness, relative to usual home care (UHC), of two Community Transitions Interventions (CTIs). The CTIs
aim to reduce recurrent stroke risk among post-stroke patients via home-based transitional care focused on better
HTN management.
Methods/Design: This 3-arm trial will randomly assign 495 black and Hispanic post-stroke home care patients with
uncontrolled systolic blood pressure (SBP) to one of three arms: UHC, UHC complemented by nurse practitioner-
delivered transitional care (UHC + NP) or UHC complemented by an NP plus health coach (UHC + NP + HC).
Both intervention arms emphasize: 1) linking patients to continuous, responsive preventive and primary care,
2) increasing patients’/caregivers’ ability to manage a culturally and individually tailored BP reduction plan, and 3)
facilitating the patient’s reintegration into the community after home health care discharge. The primary hypothesis
is that both NP-only and NP + HC transitional care will be more effective than UHC alone in achieving a SBP
reduction. The primary outcome is change in SPB at 3 and 12 months. The study also will examine cost-effectiveness,
quality of life and moderators (for example, race/ethnicity) and mediators (for example, changes in health behaviors)
that may affect treatment outcomes. All outcome data are collected by staff blinded to group assignment.
Discussion: This study targets care gaps affecting a particularly vulnerable black/Hispanic population characterized
by persistent stroke disparities. It focuses on care transitions, a juncture when patients are particularly susceptible
to adverse events. The CTI is innovative in adapting for stroke patients an established transitional care model
shown to be effective for HF patients, pairing the professional NP with a HC, implementing a culturally tailored
intervention, and placing primary emphasis on longer-term risk factor reduction and community reintegration
rather than shorter-term transitional care outcomes.
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Despite improvements in reducing stroke first-ever
occurrence, mortality and recurrence over the past few
decades [1-3], racial and ethnic disparities persist. Risk
of having a first stroke for blacks is nearly twice as high
as for whites, and blacks are more likely to die following
a stroke than are whites [4]. The risk of stroke for
Hispanics falls between that of whites and blacks [4]. A
similar pattern is seen in recurrent stroke, with blacks
and Hispanics having higher recurrence rates than
whites [5-8]. Approximately, one quarter of the strokes
that occur each year are in people who had a previous
stroke [4]. Compared to first strokes, recurrent strokes
are associated with higher mortality, greater disability,
and greater health care costs [9,10].
While reasons for racial and ethnic disparities in stroke
and stroke recurrence are complex, numerous studies
have demonstrated that blacks and Hispanics have dispro-
portionately higher rates of stroke risk factors than whites,
including uncontrolled hypertension (HTN), poorer dia-
betes control, and higher rates of hyperlipidemia [11,12].
HTN is a particularly important factor as it has been
found repeatedly to be a predictor of stroke and stroke
recurrence in the black and Hispanic populations [11-15]
and has been identified as the single most important
modifiable stroke risk factor [14,16,17]. Multiple studies
and clinical guidelines have been published indicating the
benefits of HTN control on reducing stroke risk [18-20].
Authors of a review of prospective cohort studies and a
meta-analysis of over 40 randomized controlled trials
found that in both sets of studies each 10 mmHg lower
systolic blood pressure (SBP) was associated with a one
third reduction in stroke risk [19].
Despite the benefit of HTN control, a large treatment
gap exists between the medical and behavioral regimens
recommended for recurrent stroke prevention and actual
post-stroke care received by patients [21]. The American
Heart Association and American Stroke Association
(AHA/ASA) jointly issued a statement in 2011, acknow-
ledging racial and ethnic disparities in different patients’
stroke experiences, including access to and quality of
care [22]. Our study seeks to address disparities and ser-
vice gaps by identifying and intervening with a particularly
vulnerable population - black and Hispanic patients who
have a history of stroke, currently have uncontrolled HTN
and are patients transitioning in and out of post-acute
home health care services. Data from the National Home
and Hospice Survey, which is conducted by the Centers
for Disease Control, indicate that 7% of home care pa-
tients have a history of cardiovascular disease and 41%
have HTN [23]. Each day there are approximately 1.5 mil-
lion patients enrolled in home health care [23].
Home care not only constitutes an unexplored environ-
ment to intervene to prevent stroke recurrence, it alsopresents an opportunity to do so in the context of care
transitions, a time when patients are particularly susceptible
to adverse events [24,25]. This Community Transitions
Intervention (CTI) study aims to assess the comparative ef-
fectiveness, relative to usual home care (UHC), of adding a
nurse practitioner (NP)-delivered transitional care interven-
tion or a transitional care intervention delivered by an NP +
health coach (HC). Clinical trials of NP-delivered transi-
tional care interventions have shown them to be effective in
improving outcomes of heart failure (HF) patients [24]. Tri-
als of community health worker and coaching interventions
have shown significant potential to improve blood pressure
(BP) control [26-29]. However, NP transitional care alone or
combined with HC support has never been tested as a ve-
hicle for risk reduction among post-stroke patients.
Both intervention arms have a three-fold focus: 1) link-
ing patients to continuous, rapidly responsive preventive
and primary care, 2) increasing patients’/caregivers’ ability
to manage a culturally and individually tailored BP reduc-
tion plan, and 3) facilitating the patient’s reintegration into
the community after home health care discharge. The CTI
is significant in that it targets care gaps affecting a particu-
larly vulnerable population characterized by persistent
stroke disparities (blacks/Hispanics). It is innovative in
that it adapts for stroke patients established transitional
care models shown to be effective for HF patients [26,30],
pairs the professional NP with a community HC and gives
emphasis to longer-term risk factor reduction and com-
munity reintegration rather than short-term transitional
care outcomes.
Methods/Design
The study is designed as a three-arm RCT so that we can
test individually the comparative effectiveness of adding: a)
just an NP CTI, or b) an NP +HC CTI to routine care -–
that is UHC. The primary hypothesis is that either inter-
vention will be more effective in reducing blood pressure
than the UHC condition. There is no hypothesis regarding
the relative merits of one of the intervention arms over
the other. Thus, the study is powered to compare the ef-
fects of each intervention (NP and NP + HC) to UHC.
However, in sensitivity power calculations for non-linear
change models, scenarios with different effect sizes associ-
ated with each intervention will be examined.
Setting: study site
The study is being conducted in the post-acute care div-
ision of a large, urban, nonprofit, Medicare-certified home
health organization. The majority of post-acute care stroke
patients are admitted to home care immediately after a
hospital discharge; others come through community refer-
rals (primarily physicians). All patients in the study (re-
gardless of study arm) will receive UHC (see Figure 1).
The study was approved by the Visiting Nurse Service of
Figure 1 Community Transitions Intervention study design.
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ence #I12-004).
Control condition: usual home care
UHC consists of: a physician-ordered plan of care; skilled
nursing and/or therapy services as prescribed by the med-
ical doctor; patient education, monitoring and hands-on
care; home health aide services depending on functional
deficits and availability of unpaid caregivers; and social
work services if emotional, environmental, social and/or
community resource needs are identified. All nurses and
therapists use tablet computers, electronic messaging and
an electronic health record (EHR); and have access to a
decision support system. The decision support system
includes a discretionary module on care of stroke pa-
tients that outlines information to teach the patient/
caregiver (for example, manifestations/causes/contribut-
ing factors to stroke, behaviors to manage a stroke, and
symptoms/complications to seek emergency care). The
module also gives nurses information on helping pa-
tients manage motor/sensory/cognitive deficits. Themodule emphasizes stroke recovery/rehabilitation ra-
ther than secondary prevention.
Interventions
Nurse Practitioner (NP) Arm
The study’s NPs are employed by a professional practice
group affiliated with the parent home health organization.
The practice group provides primary and specialty med-
ical services and care coordination and can bill third par-
ties. The intervention, which complements UHC, builds
on an existing 30-day transitional care program estab-
lished in the practice group. Program components are
modeled after two evidence-based models: 1) the Tran-
sitional Care Model (TCM) developed and validated for
HF patients [26], which uses an advanced practice nurse
for intervention activities, and 2) the Four Pillars of the
30-day Care Transitions Intervention® (CTI) [30], which
emphasizes patient self-management. Both models have
demonstrated effectiveness in reducing hospital read-
missions [25,31]. Because the intervention commences
only after a patient is admitted to home care, we have
















Notes: HC = health coach; NP = nurse practitioner.
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the hospital before discharge. This element has been
omitted in other tests of the TCM [32]. We also have
modified the traditional TCM in at least two other ways:
1) to allow for the inclusion of at-risk eligible patients
referred to home care from community physicians, and
2) to increase the emphasis on stroke recurrence pre-
vention - specifically on reducing SBP. We incorporated
and combined the goal of improved transitional care with
the goal of effective chronic disease self-management. The
program length of 30 days was chosen because it is the al-
lowable Medicare reimbursable timeframe for transitional
care services and thus should contribute to the sustain-
ability of the model after the grant period ends.
With intervention patients the NP is responsible for:
1) conducting a comprehensive health assessment; 2) es-
tablishing linkages with the patient’s physicians (special-
ists and primary care) and UHC nurse; 3) working with
the physicians to specify recommended medication and
behavioral regimens; 4) coordinating with the patient and
the patient’s caregivers to formulate patient goals; 5) tai-
loring the treatment plan to the patient’s preferences and
circumstances; and 6) providing collaborative problem
solving and self-management support to the patient and
caregivers. The NP patient-contact protocol includes: 3
in-home visits, 3 patient-caregiver telephone calls, and a
varied amount of inter-professional collaboration calls
over the 30-day intervention period. Between the in-home
visits, the patient-caregiver calls provide the opportunity
for the NP to review with patients/caregivers their medical
appointments, test results and medication issues and to
reinforce progress with lifestyle management. The NP also
may attend a joint visit to the patient’s primary care
physician for patients who are having difficulty with
their treatment plan. Additional resources that the NP
provides and discusses with the patient/caregiver are a
transitional care booklet that includes worksheets to be
used to develop a personal health record and an (AHA/
ASA) packet ‘Understanding and Controlling your High
Blood Pressure’ educational guide. These guides are pro-
vided in English or Spanish as preferred by the patient.
NP + health coach (HC) Arm
This arm, like the NP-only arm, complements UHC. It is
designed so that all patients receive the intensive 30-day
NP intervention as described above plus an additional
60 days of collaboration and self-management support
from a specially trained HC. The HC joins the NP at the
third patient intervention visit and subsequently provides
3 in-home visits and 3 telephone calls for HC/patient-
caregiver collaboration. The planned schedule of NP/HC
contacts is outlined in Table 1.
Home health aides and other community members
who have similar racial and ethnic backgrounds as thetarget patient population have been engaged and trained
as community health coaches for this study. The train-
ing curriculum was based on the principles of adult
learning theory, the core competencies identified by the
National Community Health Advisor study [33], and
the Training Curriculum for Health Coaches developed
by Bodenheimer at UCSF Center for Excellence in Primary
Care [34]. The coaches were trained to use motivational
interviewing strategies (for example, setting the agenda,
reflective listening, building motivation for change, goal
setting) [35] to facilitate relationship building, assist
with problem-solving, and to promote behavior change.
Training was led by one of the co-investigators (AS),
who is a member of the Motivational Interviewing Net-
work of Trainers (MINT).
The key elements of the HC role are: 1) communica-
tion with patients and their informal caregivers to pro-
mote recurrent stroke prevention awareness, education,
and understanding of risk factors and recommended med-
ical and lifestyle regimens; 2) collaborative interactions to
improve self-management; and 3) navigation and network-
ing to facilitate patients’ social and physical integration
into the community for lasting change. The HC uses the
AHA/ASA educational guide distributed by the NP, as
noted above, to support his or her efforts in working with
the patient on setting behavior change goals.
Intervention fidelity monitoring protocol
Monitoring activities are outlined below:
1. Review NP adherence to intervention protocol
Primary monitoring
a. #/% of 6 encounters planned; track #/% of 3
in-home visits and #/% of 3 telephone calls
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c. #/% of cases in which HTN management was
addressed
d. #/% of cases joint NP-HC visit was completed,
when appropriate
Supplemental monitoring
e. #/% of patients who have a joint NP-MD visit
f. # of collaborative-coordination calls per patient
2. Review health coach adherence to intervention
protocol
Primary monitoring
a. #/% of 6 encounters planned; track #/% of 3
in-home visits and #/% of 3 telephone calls
b. # of encounters above the 6 planned
c. #/% of cases in which at least 1 HTN
self-management goal was established
d. Completion rate of requested audio-recordings
e. #/% of audio-recordings in which motivational
interviewing principles were demonstrated
Supplemental monitoring
f. #/% of patients who receive a community
resource referralTable 2 Study participant eligibility criteria
Inclusion criteria Exclusion criteria
▪ Average screening systolic
BP ≥ 140 mmHg on 2 screening
visits within 7 days of each other
▪ Average screening systolic BP ≥
200 mmHg or average diastolic
BP ≥ 120 mmHg (on 3 consecutive
visits)
▪ Recently admitted to the home
care post-acute care program
▪ Dialysisa
▪ End stage renal diseasea
▪ 21 years of age or older ▪ Kidney transplanta
▪ Black and/or Hispanic ▪ Severe heart failurea
▪ Speaks English or Spanish ▪ Significant cognitive impairment.
Unable to provide informed
consent, accurate self-report,
and/or unable to participate
effectively in intervention
▪ History of stroke (ischemic
or hemorrhagic) or transient
ischemic attack
▪ HTN diagnosis ▪ Patients with upper arm
circumference ≥ 38 cm. At this
dimension our blood pressure
cuffs become inaccurate
▪ Resides in the study
catchment area
▪ Has a telephone (in order
to participate in intervention
phone sessions)
Notes: BP = blood pressure; HTN = hypertension.
aConditions require very specialized care of HTN, including different
medications and dietary/physical activity recommendations.Abbreviations; HC = health coach; HTN= hypertension;
MD= doctor of medicine, NP = nurse practitioner.
NP and HC intervention staff enter information on each
of their patient encounters in the EHR of the transitional
care program. Patient-level and aggregate reports, gener-
ated for regular review by the principal investigator, the
project manager and the field coordinator, include data on
the number and types of encounters by each discipline,
time of each encounter, and number of collaborative-
coordination calls. Data about HTN management interven-
tions and goal setting/achievement is also being extracted,
tracked, and monitored. NPs are involved in regular case
reviews. The health coaches are audio-recording encoun-
ters with 20% of their patients. These sessions are being
evaluated using the Behavior Change Counseling Index
(BECCI) [36]. The BECCI is an instrument designed for
trainers to score practitioners’ use of behavior change
counseling strategies in their patient encounters. Coa-
ches receive regular feedback on their intervention ac-
tivities by the project manager and two MINT trainers.
Eligibility and inclusion/exclusion criteria
A total of 495 black and Hispanic patients (≥21 years of
age) who have had a first time or recurrent stroke (ische-
mic or hemorrhagic) or transient ischemic attack (TIA)
and have uncontrolled SBP will be recruited: 165 random-
ized to each group. To be eligible a patient also needs to
be English or Spanish speaking and have a telephone to
use for intervention encounters. Patients are excluded if
they have a clinical condition that may require specialized
HTN management (for example, end stage renal disease,severe HF). Additional inclusion/exclusion criteria are
listed in Table 2.
Procedures
Screening
Initial identification is through a review of EHR data for
new admissions into the organization’s post-acute care
program. Electronic records were used to initially iden-
tify potential patients using a variety of International
Classification of Diseases, version 9 (ICD-9) codes for
post-stroke care (with the vast majority of patients com-
ing in with a code of 438.xx - late effects of cerebrovas-
cular disease). Confirmation of the history of stroke or
TIA was completed through patient self-report. After pa-
tients are enrolled, they are asked to sign a release for
their hospital discharge summaries so the investigator
group can retrieve additional information on their most
recent stroke. Confirmation of additional eligibility criteria
requires that the patient pass: 1) a telephone eligibility
screen, 2) an initial in-home BP check, and 3) a confirma-
tory BP check within 7 days of the initial check. These
three steps are conducted by specially trained study inter-
viewers who receive extensive didactic, role play, and field
training prior to independent deployment.
On the first BP screening visit, three readings are
taken simultaneously on both arms using a validated, au-
tomated oscillometric BP device (Microlife Watch BP,
Golden, CO, USA) and an average is provided. If a pa-
tient’s SBP is 140 mmHg or greater on either arm, the
patient is scheduled for a follow up in-home BP screening
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times on the arm that had the higher SBP reading (the
‘dominant arm’). If the average SBP is again ≥ 140 mmHg,
the level that meets our study criteria, the interviewer pro-
ceeds with recruitment, the informed consent process. Pa-
tients with a systolic BP ≥ 200 mmHg or diastolic BP of ≥
120 mmHg at the screening visits are directed to receive
immediate medical attention. If the patient is willing, an
additional BP screening visit will be scheduled for at least
48 hours after the critical BP screen visit to determine po-
tential eligibility. If the patient’s BP continues to be critical,
they will be advised to seek immediate medical attention
and will not be enrolled in the study.
Informed consent
If the patient has a SBP of 140 mmHg or greater at both
screenings then the interviewer proceeds with the in-
formed consent process. The interviewer provides the pa-
tient with the hardcopy consent and among other things
describes the three potential study groups, the content of
the interventions, the baseline and follow up interview
schedule, the sharing of information with others on the
study team and that involvement is voluntary. The inter-
viewer confirms that the patient understands what they
are consenting to, and if the patient agrees two consents
are signed: one for study files and one for the patient. In-
formed consent is obtained from each participant.
Baseline assessment
Once a consent form is signed, the interviewer proceeds
directly with the baseline assessment. The assessment is
a structured interview, largely made of up self-report
measures. (See Measurements section below).
Randomization and blinding
Following the baseline interview, subjects are randomized
to one of three arms. Upon randomization to one of the
intervention arms, the UHC nurse who is designated as
the main nurse organizing and providing routine home
health visits to the patient is sent a secure Email message
indicating the patient’s involvement in the CTI. The Email
outlines the objectives of the program and provides infor-
mation on how to contact the transitional care NP involved
in the case. As necessary/appropriate, the NP contacts the
UHC nurse, just as the NP contacts the physician or any
other health care provider of the patient as medically ne-
cessary. Throughout the course of the study, field inter-
viewers collecting baseline and outcome data are blinded
to the patient assignment group.
Anticipated study characteristics
The gender distribution is expected to reflect the home
care population with the targeted clinical conditions. Be-
cause the goal of study is to determine whether theinterventions will improve blood pressure control in ra-
cial minorities after stroke, the participants in this study
will be self-identified as black or Hispanic. Based on
available organization data and prior studies, the en-
rolled sample is expected to be 65% black/35% Hispanic;
40% male/60% female; with a mean age of 67 years.
Measurements
Data sources
To achieve our specific aims, we will make use of data
from: 1) patient assessments and interviews conducted
during the initial phone screen, at baseline (enrollment
in the study), and 3 and 12 months post-study enroll-
ment; and 2) intervention cost data collected especially
for this study. Information to be obtained is summarized
in Table 3. Additionally, patient-level clinical and func-
tional assessment data derived from OASIS, the nationally
mandated home care Outcomes Assessment and Informa-
tion Set will be used to assess potential differences in
those participating in the study and those who declined.
This will be used for discussion of the generalizability of
our findings.
Primary outcome: change in systolic blood pressure
The primary outcome is change in SBP from baseline to 3
and 12 months. As with the baseline interview, patients are
assessed with a validated, automated oscillometric BP de-
vice (Microlife Watch BP, Golden, CO, USA). The average
of the BP measurements from the two enrollment screen-
ing visits will be used for comparative analysis to the follow
up measurements. At the 3- and 12-month follow up eval-
uations, the BP will be measured by interviewers, blinded
to group assignment, 3 times on the dominant arm identi-
fied at baseline and the average will be used for analysis.
Secondary outcomes: cost-effectiveness, patient function,
and quality of life
Costs will focus on direct costs including costs of the in-
terventions, home care utilization, hospital and emer-
gency department use, outpatient visits and medication
regimens. Patient function and health-related quality of
life will be assessed with a modified self-report Barthel
Index [37] and the EuroQol [38]. See Table 3.
Exploratory outcomes: moderators and mediators
Data are being collected so that moderators and media-
tors that may affect treatment outcomes can be ex-
plored. Moderators include race and ethnicity (that is
black/Hispanic) differences and baseline HTN severity
(for example, Stage 1 (SBP = 140 to 159 mmHg) versus
Stage 2 (SBP ≥ 160 mmHg)). Mediators include changes
in health behaviors (for example, diet, physical activity,
weight loss, medication adherence) and antihypertensive
medication intensification.
Table 3 Information to be collected and used in analysis
Baseline 3 Months 12 Months
Patient Characteristics
Basic sociodemographics: age, sex, race, ethnicity, preferred language to use, living situation,
education, health literacy
X
Marital status, employment status, income X X X
Acculturation: place of birth, parent and grandparent place of birth, length of time in US X
Executive Cognitive Function (FAB) X
Stroke, HTN and hospitalization history; co-morbidities (modified Charlson) X X X
Clinical and functional outcomes
Primary outcome
Blood pressure measurement X X X
Secondary outcomes
Cost-effectiveness X X X
Health-related quality of life (EuroQol) X X X
ADL/Functional Status (modified Barthel/Rankin for patient self-report) X X X
Physical function (PROMIS®) X X X
New cardiovascular events X X
Exploratory outcome mediators
Knowledge of HTN management X X X
Stroke literacy questions (Willey) X X X
Adherence to regimen (Morisky) X X X
Beliefs about medications (BMQ) X X X
Linkage to PCP X X X
Chronic condition management (PACIC) X X X
General self-efficacy scale (Lorig) X X X
Lifestyle management: diet/sodium intake (modified CATCH), physical activity (IPAQ), tobacco, alcohol
and drug use, body mass index
X X X
Depression (PROMIS®) X X X
Medication profile X X X
Organizational and system costs
Intervention costs: nurse practitioner and health coach time, patient educational material X X
Home care-related costs: nurse, therapy, social work, and aide home care visits X X
Overall medical costs: nights in hospital, ED visits, physician visits, medications X X
Notes: Barthel/Rankin [37,53]; FAB = Frontal Assessment Battery [54]; Charlson, modified self-report [55,56]; EuroQol [38]; PROMIS® [57]; Willey [58]; Morisky, 8-item
version [59]; BMQ [60], PACIC = Patient Assessment of Chronic Illness Care, modified subscales [61]; Lorig [62]; CATCH [63]; IPAQ = International Physical Activity
Questionnaire [64,65]; PROMIS® depression [66]; ED = emergency department; ADL = activities of daily living; PCP = primary care provider; HTN = hypertension.
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Data analyses for primary outcome: SBP
The main hypothesis is that those assigned to the inter-
vention groups will, on average, exhibit greater 3-month
and 12-month decreases in SBP than those assigned to
the usual care condition. The primary proposed analyses
will use mixed random effects models, and a full infor-
mation maximum likelihood (FIML) approach, with
sensitivity analyses using generalized estimating equa-
tion (GEE) regression models. The change from pre- to
post-treatment values of SBP will be modeled as func-
tions of time, treatment and the interaction of time andtreatment. The general longitudinal mixed effects model,
using SAS PROC MIXED (SAS, Cary, NC, USA), will be
used to model serial correlations and group heterogeneity
in residual variances if needed. The intent-to-treat (ITT)
analyses will permit all individuals with at least one
observation to be included. If a non-linear pattern of
change is observed, non-linear models will be used in
sensitivity analyses.
Prior to analyses, baseline values of all variables will be
examined in order to determine if any covariates require
modeling due to imbalance among groups. Examination of
baseline differences on key variables between completers
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about the nature of the missing data.
Power for SBP rate of change
Power was calculated, examining the rate of change,
including all three waves in the analyses. The following
assumptions were used: R = 0.90 (reliability); pooled
σ = 20.75; δ = 5, 6, 7 (SBP point reduction per year in the
intervention groups relative to the UHC group reduction);
d = δ/σ (where δ is point reduction per year and d is
Cohen’s d for the rate of change); ρ = 0.6 is the average
correlation between baseline and follow up assessments;
Tn = 3 time points (baseline, 3 month and 12 month). The
formulas from Diggle, Liang and Zeger (1994) were used
[39]: the power calculation demonstrates that under ITT,
we can detect a rate of reduction in SBP equivalent to
5.40 mmHg which translates to relatively small effect sizes
using Cohen’s d. It is also noted that the assumed standard
deviation was conservatively posited to be quite large
(pooled estimate of around 21). If a smaller standard devi-
ation is observed, power will be greater. Thus, a sample
size of 165 per group was proposed.
For the non-linear, longitudinal change sensitivity ana-
lyses [40], the assumptions were the same as above, and
an endpoint reduction in SBP of 6 points was posited.
Assuming a non-linear decline function and differential
treatment effects, power was greater than 0.80 to detect
small effects (for example, a 0.5 point reduction) in one
intervention group at 3 months and medium to large
effects (2.5 to 5 point reduction in SBP) in the second
group at 3 months, with a net reduction of 6 points by
study end in both groups.
Discussion
The cumulative 5-year risk of having a recurrent stroke
after a person’s first-ever stroke is over 30%, and the 30-
day fatality risk associated with secondary strokes has
been reported to be 40 to 50%, which is significantly
higher than first stroke fatality rates [41,42]. Blacks and
Hispanics have higher risk of recurrence than whites
[5,7,8]. A contributor to this ongoing risk of stroke sur-
vivors is ineffective recurrent stroke preventive inter-
ventions. Our interventions are designed to specifically
address HTN, a major risk factor for strokes and recur-
rent strokes, and are built on NP and HC models found
to be successful in addressing other clinical conditions
and established in other care settings. The NPs are posi-
tioned to complement UHC services by assessing and
addressing hospitalization risk factors that are common
during transitional care periods, while also providing a
specific HTN management intervention geared toward
preventing stroke recurrence. Both the NP and NP +
HC interventions expand on the usual transitional care
focus, which is on hospital discharges and preventingrehospitalization, by focusing on longer-term stroke risk
prevention, community provider connections to facili-
tate long-term chronic care management, and reintegra-
tion into the community.
Our interventions were informed by models that showed
promise in other settings. Focus groups and individual in-
terviews were also conducted with black and Hispanic
post-stroke patients who had received home care and their
caregivers to further inform our intervention approach
along with our enrollment efforts. During these focus
groups, post-stroke patients expressed fear of research and
lack of trust in researchers. They suggested we might
counter these fears by making sure that potential patients
are able to get a very clear understanding of the study and
their expected involvement. Operationally, this led us to
simplify the language used in describing the study: for ex-
ample, the randomization process (including being clear
about the possibility of being placed in the usual care
group) and the intent of the interventions. We also built
more time into the recruitment calls and in-person con-
senting process so that the patients are free to ask all their
questions. In addition, field staff were trained in the ‘teach
back’ method - asking patients to describe in their own
words what the initiative was about and what their com-
mitment was in order to determine areas that needed fur-
ther clarification. Lastly, we incorporated the suggestion of
focus group members that we stress the useful knowledge
gained through research and how patients are the ones
with the important information.
The intervention approach already stressed patient-
centeredness in goal setting, but focus group findings
led us to enhance staff training to further address the
cultural issues that came up at our meetings. For ex-
ample, to address the issue of trust or rather distrust in
the medical care systems, we instituted staff discussions
and practice sessions on how to maintain trust (for ex-
ample, reflective listening, following up with community
referrals when requested, addressing other clinical con-
ditions if priority to the patient). Some of our focus
group participants also expressed a sense of inevitability
to their stroke experience and the possibility of having
another stroke. These feelings seem to have been influ-
enced partly by the view that chronic disease, hyperten-
sion, and diabetes are ‘passed down’ in the family. During
our staff training, we discussed the implications of these
beliefs (for example, how they may impact a person’s self-
management behavior), how to identify these beliefs, and
how to address them (for example, additional education).
We also were guided by our participants to engage family
and others who provided the patient’s primary social
support if the patient indicated that this was desirable, to
take the time to address medication administration and
side effect questions and to explore patients’ attitudes and
beliefs about medications - elements all integrated into
Feldman et al. Trials  (2015) 16:32 Page 9 of 11the intervention approach. Additional direction for inter-
vention staff on how to recognize depression and isolation
risk was provided in the training as these were areas that
our focus group informants felt could hinder adherence to
recommended management guidelines and their recovery.
Two significant issues related to BP criteria for patient
eligibility arose shortly before and after enrollment began,
and both had potentially significant operational implica-
tions. A few weeks before launch the Program Advisory
Committee for the Center for Stroke Disparities Solutions
(CSDS) [43], parent of our study, advised the team to mod-
ify the BP eligibility screening process. Initially, the proto-
col was designed to determine patient eligibility based on a
single face-to-face encounter in which the average of 3 SBP
readings needed to be ≥ 140 mmHg after the patient passed
other eligibility screening questions described above. The
revised protocol calls for 2 face-to-face interviews in which
3 BP readings are taken and need to result in an average
SBP of ≥ 140 mmHg in both interviews. Currently, there is
no widely accepted scientific standard for enrolling patients
in BP studies; some use historical data in medical records
to identify potential study subjects [44,45], some enroll pa-
tients if they simply have a HTN diagnosis [46], some allow
enrollment of those in pre-HTN stage [47], others adopt a
higher SBP threshold of ≥ 150 mmHg at the time of enroll-
ment [48] and some include patients with single BP mea-
surements in the uncontrolled HTN range [49,50]. The
intent of the more stringent screen employed by our trial is
to increase the likelihood of enrollment of the intended
target population - those with uncontrolled HTN. Adjust-
ments to our workflow and budget were implemented,
although it was unclear how many people would drop out
after the second BP screening visit. Data from this revised
screening process will help to inform future studies. As
of 5 September 2014, of the 97 patients who passed the
first BP screen, 65 (67%) met the SBP threshold at the
second BP screen.
The second BP threshold issue that came up shortly
after enrollment began derived from publication of the
2014 Evidence-Based Guideline for the Management of
High Blood Pressure in Adults [51]. One of the 9 recom-
mendations made is to treat to a goal of SBP < 150 mmHg
for the general population aged 60 years and over, a depart-
ure from the prior guideline [52], which recommended the
SBP goal of < 140 mmHg for all patients. None of the new
recommendations addressed the goal SBP for post-stroke
patients. We expect that around 60% of the patients en-
rolled in our study will be aged 60 years or over. Since
there is a body of evidence showing the benefit of lower
SBP for stroke risk reduction, and after a discussion
with HTN specialists at the Center for Stroke Disparities
Solutions, we did not alter our intervention approach to
increase our SBP target to < 150 mmHg. However, there
is some concern that primary care providers overseeingthe long-term care of these patients may be influenced
by these published guidelines and decline to more ag-
gressively treat patients with SBP levels between 140
and 149 mmHg.
Results of this trial will provide important information
on the design of interventions to address treatment gaps
and disparities in recurrent stroke prevention for vulner-
able black and Hispanic populations. The trial focuses
on care transitions, a juncture when patients are particu-
larly susceptible to adverse events. The interventions are
innovative in adapting for stroke patients an established
transitional care model shown to be effective for HF pa-
tients, pairing the professional NP with a HC, tailoring
the interventions for black and Hispanic patients re-
spectively, and placing primary emphasis on longer-term
risk factor reduction and community reintegration ra-
ther than shorter-term transitional care outcomes.
Trial status
Patient enrollment began in January 2014. Enrollment
period is expected to be 30 months.
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